Karo Bio Announces That Merck & Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration’s lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

source : www.medicalnewstoday.com

Related News:

• EXPOSED: "Scandalous Abuse" of the Elderly Being Killed With Psychiatric Medications
• Big Pharma executive murders 8-year-old son with Xanax and Ambien (opinion)
• CREON(R) (pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption In Children With Cystic Fibrosis
• Older Women with Gout at Risk of MI (CME/CE)
• Designing Easy-To-Use Products With The Help Of Arthritis Simulation Gloves
• Safer Hip, Knee And Dental Implants With Smart Coating
• Sutures Cause Fewer Complications Than Staples With Cesarean Deliveries
• Heal yourself in 15 days with the Health Ranger’s living juice recipe (part five)
• SMFM: Gene Variants Linked to Preterm Labor (CME/CE, with video)
• Brain Dopamine Receptor Density Correlates With Social Status

Details :
Submited at Sunday, November 29th, 2009 at 7:00 am on Endocrinology by jessica
Comment RSS 2.0 - leave a comment - trackback